DxTerity Diagnostics IFN-1 Test
DxTerity Diagnostics has launched its IFN-1 Test to help guide treatment of patients with systemic lupus erythematosus. The test measures Type-1 Interferon (IFN-1), a biomarker that indicates SLE disease severity and prognosis by measuring the expression levels of four genes associated with IFN-1 activity. By identifying patients as IFN-1 high or low, healthcare providers can make more informed treatment decisions. Los Angeles-based DxTerity noted the recent approval by the US Food and Drug Administration of AstraZeneca's Saphnelo (anifrolumab), a Type-1 Interferon receptor blocker that gives rheumatologist a new treatment option to mange lupus.